1. Home
  2. TSLX vs MESO Comparison

TSLX vs MESO Comparison

Compare TSLX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

N/A

Current Price

$18.47

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$17.16

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TSLX
MESO
Founded
2010
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.1B
IPO Year
2011
2005

Fundamental Metrics

Financial Performance
Metric
TSLX
MESO
Price
$18.47
$17.16
Analyst Decision
Buy
Strong Buy
Analyst Count
9
1
Target Price
$21.61
N/A
AVG Volume (30 Days)
433.8K
179.9K
Earning Date
05-05-2026
02-26-2026
Dividend Yield
10.82%
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$629.74
Revenue Next Year
$1.20
$30.65
P/E Ratio
$121.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.04
$13.05
52 Week High
$24.79
$21.50

Technical Indicators

Market Signals
Indicator
TSLX
MESO
Relative Strength Index (RSI) 46.23 53.65
Support Level $17.20 $16.56
Resistance Level $18.65 $17.33
Average True Range (ATR) 0.33 0.47
MACD -0.12 -0.04
Stochastic Oscillator 21.55 32.80

Price Performance

Historical Comparison
TSLX
MESO

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: